Pablo Mozas

731 total citations
37 papers, 284 citations indexed

About

Pablo Mozas is a scholar working on Pathology and Forensic Medicine, Oncology and Genetics. According to data from OpenAlex, Pablo Mozas has authored 37 papers receiving a total of 284 indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Pathology and Forensic Medicine, 20 papers in Oncology and 15 papers in Genetics. Recurrent topics in Pablo Mozas's work include Lymphoma Diagnosis and Treatment (31 papers), Viral-associated cancers and disorders (16 papers) and Chronic Lymphocytic Leukemia Research (15 papers). Pablo Mozas is often cited by papers focused on Lymphoma Diagnosis and Treatment (31 papers), Viral-associated cancers and disorders (16 papers) and Chronic Lymphocytic Leukemia Research (15 papers). Pablo Mozas collaborates with scholars based in Spain, Italy and Czechia. Pablo Mozas's co-authors include Julio Delgado, Armando López‐Guillermo, Alfredo Rivas‐Delgado, Tycho Baumann, Andrea Rivero, Laura Magnano, Neus Villamor, Elı́as Campo, Eva Giné and Ferran Nadeu and has published in prestigious journals such as SHILAP Revista de lepidopterología, Blood and Cancer.

In The Last Decade

Pablo Mozas

33 papers receiving 277 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Pablo Mozas Spain 9 221 144 126 83 35 37 284
M. van ‘t Veer Netherlands 4 209 0.9× 161 1.1× 124 1.0× 35 0.4× 22 0.6× 5 278
Felicia Gomez United States 4 200 0.9× 137 1.0× 114 0.9× 52 0.6× 10 0.3× 8 250
Georg Lenz Germany 2 240 1.1× 184 1.3× 85 0.7× 56 0.7× 22 0.6× 2 265
Massimo Federico Italy 8 138 0.6× 111 0.8× 39 0.3× 31 0.4× 12 0.3× 53 245
Maria Cristina Pirosa Switzerland 10 156 0.7× 119 0.8× 52 0.4× 46 0.6× 8 0.2× 28 305
Antonella Anastasia Italy 10 216 1.0× 161 1.1× 78 0.6× 40 0.5× 8 0.2× 21 284
Jiří Mayer Czechia 7 309 1.4× 249 1.7× 153 1.2× 25 0.3× 11 0.3× 14 386
Eugene Zhu United States 8 155 0.7× 164 1.1× 123 1.0× 30 0.4× 5 0.1× 11 301
Nichola Webster United Kingdom 4 253 1.1× 152 1.1× 129 1.0× 57 0.7× 3 0.1× 9 296
H. Tilly France 4 204 0.9× 160 1.1× 76 0.6× 19 0.2× 9 0.3× 7 229

Countries citing papers authored by Pablo Mozas

Since Specialization
Citations

This map shows the geographic impact of Pablo Mozas's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pablo Mozas with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pablo Mozas more than expected).

Fields of papers citing papers by Pablo Mozas

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Pablo Mozas. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pablo Mozas. The network helps show where Pablo Mozas may publish in the future.

Co-authorship network of co-authors of Pablo Mozas

This figure shows the co-authorship network connecting the top 25 collaborators of Pablo Mozas. A scholar is included among the top collaborators of Pablo Mozas based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Pablo Mozas. Pablo Mozas is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Sorigué, Marc, Miloš D. Miljković, & Pablo Mozas. (2025). PET scan for the detection of histological transformation of follicular lymphoma: A systematic review of diagnostic performance. Blood Reviews. 71. 101270–101270.
2.
3.
Martı́nez, Carmen, Antonio Gutiérrez, Laura Magnano, et al.. (2024). Efficacy of escalating therapy with brentuximab vedotin‐AVD in advanced stage Hodgkin lymphoma patients with positive interim positron emission tomography after ABVD. Hematological Oncology. 42(5). e3299–e3299. 1 indexed citations
4.
Mozas, Pablo, Jorge Sierra, Josep Nomdedéu, et al.. (2024). Risk scores predicting disease progression in early‐stage chronic lymphocytic leukemia: Comparative analysis and usefulness of IGHV subset #2 to improve their accuracy. Cancer. 131(1). e35552–e35552. 1 indexed citations
5.
Nadeu, Ferran, Silvia Martín, Pablo Mozas, et al.. (2023). MALAT1 expression is associated with aggressive behavior in indolent B-cell neoplasms. Scientific Reports. 13(1). 16839–16839. 5 indexed citations
6.
Rivero, Andrea, Pablo Mozas, Laura Magnano, & Armando López‐Guillermo. (2023). Novel targeted drugs for follicular and marginal zone lymphoma: a comprehensive review. Frontiers in Oncology. 13. 1170394–1170394. 6 indexed citations
7.
Mozas, Pablo, et al.. (2022). Methodological and conceptual challenges to the flow cytometric classification of leukemic lymphoproliferative disorders. Critical Reviews in Clinical Laboratory Sciences. 60(2). 83–100. 1 indexed citations
8.
Marcé, Sílvia, Gustavo Tapia, Jordi Juncà, et al.. (2022). Flow cytometry to detect bone marrow involvement by follicular lymphoma. Cytometry Part B Clinical Cytometry. 102(6). 427–439. 3 indexed citations
9.
Orgueira, Adrián Mosquera, José Ángel Díaz Arias, Marta Sonia González, et al.. (2022). Personally Tailored Survival Prediction of Patients With Follicular Lymphoma Using Machine Learning Transcriptome-Based Models. Frontiers in Oncology. 11. 705010–705010. 7 indexed citations
10.
Oliver‐Caldés, Aina, Ester Lozano, David F. Moreno, et al.. (2022). Long-Term Responders After Autologous Stem Cell Transplantation in Multiple Myeloma. Frontiers in Oncology. 12. 5 indexed citations
11.
Mozas, Pablo, Andrea Rivero, & Armando López‐Guillermo. (2021). Past, present and future of prognostic scores in follicular lymphoma. Blood Reviews. 50. 100865–100865. 11 indexed citations
12.
Mozas, Pablo, Marc Sorigué, & Armando López‐Guillermo. (2021). Actualización en el diagnóstico, pronóstico y tratamiento del linfoma folicular. Medicina Clínica. 157(9). 440–448. 5 indexed citations
13.
Mozas, Pablo, Andrea Rivero, Alfredo Rivas‐Delgado, et al.. (2021). Age and comorbidity are determining factors in the overall and relative survival of patients with follicular lymphoma. Annals of Hematology. 100(5). 1231–1239. 5 indexed citations
14.
Mozas, Pablo, Andrea Rivero, Alfredo Rivas‐Delgado, et al.. (2021). Prognostic ability of five clinical risk scores in follicular lymphoma: A single‐center evaluation. Hematological Oncology. 39(5). 639–649. 5 indexed citations
15.
Mozas, Pablo, Marc Sorigué, Alfredo Rivas‐Delgado, et al.. (2020). The interval between frontline treatment and the second relapse (PFS2) predicts survival from the second relapse in follicular lymphoma patients. European Journal Of Haematology. 106(3). 428–432. 1 indexed citations
16.
Mozas, Pablo, Ferran Nadeu, Alfredo Rivas‐Delgado, et al.. (2020). Patterns of change in treatment, response, and outcome in patients with follicular lymphoma over the last four decades: a single-center experience. Blood Cancer Journal. 10(3). 31–31. 25 indexed citations
17.
Mozas, Pablo, Alfredo Rivas‐Delgado, Andrea Rivero, et al.. (2020). High serum levels of IL-2R, IL-6, and TNF-α are associated with higher tumor burden and poorer outcome of follicular lymphoma patients in the rituximab era. Leukemia Research. 94. 106371–106371. 11 indexed citations
18.
Rivas‐Delgado, Alfredo, Laura Magnano, Olga García, et al.. (2018). Response duration and survival shorten after each relapse in patients with follicular lymphoma treated in the rituximab era. British Journal of Haematology. 184(5). 753–759. 44 indexed citations
19.
Delgado, Julio, Michael Doubek, Tycho Baumann, et al.. (2017). Chronic lymphocytic leukemia: A prognostic model comprising only two biomarkers ( IGHV mutational status and FISH cytogenetics) separates patients with different outcome and simplifies the CLL‐IPI. American Journal of Hematology. 92(4). 375–380. 66 indexed citations
20.
Rivas‐Delgado, Alfredo, Laura Magnano, Pablo Mozas, et al.. (2017). Progression‐free survival shortens after each relapse in patients with follicular lymphoma treated in the rituximab era. Hematological Oncology. 35(S2). 360–361. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by M. van ‘t Veer Breakdown of academic impact, for papers by Felicia Gomez Breakdown of academic impact, for papers by Georg Lenz Breakdown of academic impact, for papers by Massimo Federico Breakdown of academic impact, for papers by Maria Cristina Pirosa Breakdown of academic impact, for papers by Antonella Anastasia Breakdown of academic impact, for papers by Jiří Mayer Breakdown of academic impact, for papers by Eugene Zhu Breakdown of academic impact, for papers by Nichola Webster Breakdown of academic impact, for papers by H. Tilly
Rankless by CCL
2026